Stockscreener 앱 받기
1.80
1.64%
-0.03
시간 외 거래:
1.86
0.06
+3.33%
Medicus Pharma Ltd 주식(MDCX)의 최신 뉴스
Medicus Pharma completes patient enrollment for phase 2 BCC treatment study - MSN
Medicus Pharma completes enrollment in Phase 2 skin cancer microneedle study - Proactive financial news
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Columbia Daily Tribune
Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK - TMX Newsfile
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC - Dermatology Times
Small cap wrap: EnWave, Medicus Pharma, Ocean Power Technologies, EDM Resources, C3 Metals… - Proactive financial news
Medicus Pharma completes enrollment for Phase 2 basal cell carcinoma study - Proactive financial news
Medicus Pharma Completes Patient Enrollment for Phase 2 BCC Treatment Study - TipRanks
Medicus Pharma (MDCX) Analyst Rating Maintained by D. Boral Capi - GuruFocus
Medicus Pharma completes enrollment of 90 patients for Phase 2 study - TipRanks
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Manila Times
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) - GlobeNewswire
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - Greenville Online
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025 - Victorville Daily Press
Medicus Pharma’s Warrant Inducement Agreement Announced - TipRanks
Medicus Pharma Elevates President Carolyn Bonner to CFO as Clinical Pipeline Accelerates - MyChesCo
Medicus Pharma Ltd. To Present at Brookline Capital Markets - Daytona Beach News-Journal
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE - Daytona Beach News-Journal
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin - The Asheville Citizen Times
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing - The Times Telegram
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject - Daytona Beach News-Journal
Medicus Pharma secures $5.1 million from warrant exercise agreement By Investing.com - Investing.com Nigeria
Medicus Pharma secures $5.1 million from warrant exercise agreement - Investing.com India
0.79%
0.44%
자본화:
|
볼륨(24시간):